|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||17.14 - 17.14|
|52 Week Range||12.60 - 17.14|
|Beta (3Y Monthly)||0.55|
|PE Ratio (TTM)||28.59|
|Forward Dividend & Yield||0.22 (1.29%)|
|1y Target Est||N/A|
Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a leading global producer of plasma-derived medicines, will present the final and complete clinical, biomarker and neuroimaging results of its AMBAR (Alzheimer Management by Albumin Replacement) clinical trial at the Clinical Trials on Alzheimer's Disease (CTAD) Conference in San Diego, Calif. (USA).
Moody's Investors Service ("Moody's") has today affirmed the Ba3 corporate family rating (CFR), Ba3-PD probability of default rating (PDR), and B2 senior unsecured rating of Grifols S.A. (Grifols), a Spanish healthcare company primarily focused on human blood plasma-derived products and transfusion medicine. At the same time, Moody's has assigned a Ba2 rating to the proposed USD5.0 billion equivalent worth of senior bank facilities to be issued by Grifols, Grifols World Wide Operations Ltd., and Grifols Worldwide Operations USA, Inc., both wholly-owned subsidiaries of Grifols.
We can judge whether Grifols SA (NASDAQ:GRFS) is a good investment right now by following the lead of some of the best investors in the world and piggybacking their ideas. There's no better way to get these firms' immense resources and analytical capabilities working for us than to follow their lead into their best ideas. […]
It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...
Shares of Grifols popped in massive volume Friday after the Spain-based pharmaceutical company gained Food and Drug Administration approval for an immunodeficiency treatment.
The following is a roundup of the top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs July 3.) • Abbott Laboratories (NYSE: ABT ) • Apellis ...
Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Grifols S.A. Paris, May 16, 2019 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Grifols S.A. and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.
This article is for investors who would like to improve their understanding of price to earnings ratios (P/E ratios). To keep it practical, we'll show how Grifols, S.A.'s (BME:GRF) P/E ratio could help you assess the value on offer...
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Looking at Grifols, S.A.'s (BME:GRF) earnings update in December 2018, the cons...
Spanish blood products company Grifols said on Thursday it has signed a strategic alliance with Shanghai RAAS as it looks to increase its sales of plasma-derived products in China. Under the agreement, the Catalan company will take a 26.2 percent stake in Shanghai RAAS in exchange for a stake of 45 percent (with 40 percent voting rights) in its U.S. division Grifols Diagnostic Solutions (GDS). Grifols said that no external financing was required to fund the transaction which is expected to close in the second half of 2019 pending regulatory approval.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Dividends play an important role in compounding Read More...
Small-cap biotech Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL )'s shares were advancing Wednesday after it announced an agreement to commercialize fostamatinib, its autoimmune disorder drug. What Happened ...
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like to learn about Return On Equity (ROE) and why it Read More...